NEW YORK (GenomeWeb News) – Agendia said yesterday that it plans to seek expanded clearance from the US Food and Drug Administration for the use of its MammaPrint breast cancer prognosis test in patients over the age of 60.
 
The Amsterdam-based company said it has completed a study that has shown the test to be useful in assessing the risk of the recurrence of breast cancer in older, post-menopausal patients.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.